Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia

Biological Psychiatry

Volumn 43, Issue 1, 1998, Pages 24-30

  Thibaut, Florence ^a   Ribeyre, Jean Marie ^a   Dourmap, Nathalie ^b   Ménard, Jean François ^c   Dollfus, Sonia ^a   Petit, Michel ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b CNRS   (France)

^c Univ de Médecine   (France)

Author keywords

Deficit syndrome; HVA; NHPG; Plasma concentrations; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; CHLORPROMAZINE; HOMOVANILLIC ACID; NEUROLEPTIC AGENT; TROPATEPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

AGED; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0031965320     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00023-1     Document Type: Article

References (53)

1. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. 1987;American Psychiatric Press, Washington, DC.
2. Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research A review of methodology . Schizophr Bull. 18:1992;123-148.
3. Amin F, Davidson M, Kahn RS, et al. Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr Bull. 21:1995;53-66.
4. Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev. 35:1983;53-68.
5. Bowers MB. Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry. 31:1974;50-54.
6. Bowers MB, Swigar ME, Jatlow PL. Sex differences in plasma homovanillic acid in acute psychosis. N Engl J Med. 308:1983;845-846.
7. Brambilla F, Marini S, Saito A, et al. Noradrenergic and dopaminergic interrelation in schizophrenia. Psychiatry Res. 53:1994;231-242.
8. Breier A, Wolkowitz OM, Roy A, et al. Plasma norepinephrine in chronic schizophrenia. Am J Psychiatry. 147:1990;1467-1470.
9. Buchanan RW, Kirkpatrick B, Heinrichs DW, et al. Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry. 147:1990;290-294.
10. Buchanan RW, Breier A, Kirkpatrick B, et al. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry. 150:1993;59-65.
11. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia The concept . Am J Psychiatry. 145:1988;578-583.
12. Carpenter WT, Buchanan RW, Kirkpatrick B, et al. Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry. 50:1993;825-831.
13. Davidson M, Davis KL. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry. 45:1988;561-563.
14. Davidson M, Kahn R, Kooper M, et al. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry. 48:1991;910-913.
15. Davila R, Manero E, Zumarraga AI, et al. Plasma homovanillic acid as predictor of response to neuroleptics. Arch Gen Psychiatry. 45:1988;564-567.
16. Dollfus S, Petit M. Negative symptoms in schizophrenia Their evolution during an acute phase . Schizophr Res. 17:1995;187-194.
17. Dollfus S, Petit M, Lesieur P, et al. Principal components analysis of PANSS and SANS-SAPS global ratings in schizophrenic patients. Eur J Psychiatry. 6:1991;251-259.
18. Doran AR, Pickar D, Labarca R, et al. Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients. Psychopharmacol Bull. 21:1985;694-697.
19. Dourmap N, Michael-Titus A, Costentin J. Differential effect of intrastriatal kainic acid on the modulation of dopamine release by mu- and delta-opioid peptides A microdialysis study . J Neurochem. 58:1992;709-713.
20. Elsworth JD, Redmond DE, Roth RH. Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol (MHPG) as indices of brain norepinephrine metabolism in primates. Brain Res. 235:1982;115-124.
21. Fenton WS, McGlashan TH. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry. 49:1992;179-185.
22. Foster P. Neuroleptic equivalence. Pharmacol J. 30:1989;431-432.
23. Garcia A, Galinowski A, Guicheney P, et al. Free and conjugated plasma homovanillic acid in schizophrenic patients. Biol Psychiatry. 26:1989;87-96.
24. Gelernter J, Van Kammen DP. Schizophrenia Instability in norepinephrine, serotonin and γ-aminobutyric acid systems . Int Rev Neurobiol. 29:1990;309-347.
25. Glowinski J, Herve D, Tassin JP. Heterologous regulation of receptors on target cells of dopamine neurons in the prefrontal cortex, nucleus accumbens, and striatum. Ann NY Acad Sci. 537:1986;112-123.
26. Green AI, Alam MY, Boshes RA, et al. Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res. 10:1993;33-37.
27. Kahn RS, Davis KL. New developments in dopamine and schizophrenia. Bloom FE, Kupfer DJ. Psychopharmacology The Fourth Generation of Progress . 1995;1193-1203 Raven Press, New York.
28. Kaminski R, Powchick P, Warne PA, et al. Measurement of plasma homovanillic acid concentrations in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 14:1990;271-287.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:1987;261-276.
30. Kemali D, Del Vecchio M, May M. Increased norepinephrine levels in CSF and plasma of schizophrenic patients. Biol Psychiatry. 17:1982;711-717.
31. Kirkpatrick B, Buchanan RW. Anhedonia and the deficit syndrome of schizophrenia. Psychiatry Res. 31:1990;25-30.
32. Kirkpatrick B, Buchanan RW. The neural basis of the deficit syndrome of schizophrenia. J Nerv Ment Dis. 178:1990;545-555.
33. Kirkpatrick B, Buchanan RW, McKenney PD, et al. The schedule for the deficit syndrome An instrument for research in schizophrenia . Psychiatry Res. 30:1989;119-123.
34. Kirkpatrick B, Buchanan RW, Breier A, et al. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res. 47:1993;47-56.
35. Kopin IJ, Gordon EK, Jimerson DC, et al. Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science. 219:1983;73-75.
36. Kopin IJ, Oliver JA, Polinsky RJ. Relationship between urinary excretion of homovanillic acid and norepinephrine metabolites in normal subjects and patients with orthostatic hypotension. Life Sci. 43:1988;125-131.
37. Muscettola G, Barbato G, De Bartalomeis A, et al. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free patients schizophrenia. Psychiatry Res. 33:1990;259-267.
38. Nibuya M, Kanba S, Sekiya U, et al. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry. 38:1995;50-56.
39. Pickar D, Labarca R, Doran A, et al. Longitudinal measurements of plasma homovanillic acid levels in schizophrenic patients Implications for regional brain dysfunction . Arch Gen Psychiatry. 43:1986;641-679.
40. Pickar D, Breier A, Wolkowitz OM, et al. Time dependent effects of neuroleptic treatment on positive and negative symptoms Relationship to levels of plasma homovanillic acid (HVA) . Clin Neuropharmacol. 9:(suppl 4):1986;412-414.
41. Pickar D, Breier A, Doran AR, et al. Cerebrospinal fluid and plasma monoamine metabolites and psychotic symptomatology in schizophrenic patients. Arch Gen Psychiatry. 47:1990;641-648.
42. Pol O, Campmany L, Gil M, Armario A. Behavioral and neurochemical changes in response to acute stressors Influence of previous chronic exposure to immobilization . Pharmacol Biochem Behav. 42:1992;407-412.
43. Post RM, Fink E, Carpenter WT, et al. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry. 32:1975;1063-1069.
44. Ribeyre JM, Lesieur P, Varoquaux O, et al. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry. 36:1994;230-236.
45. Ribeyre JM, Dollfus S, Lesieur P, et al. Instrument d'évaluation du syndrome déficitaire de la schizophrénie [Schedule for the deficit syndrome (SDS)]. L'encéphale. 20:1994;413-419.
46. Scheinin H. Enhanced noradrenergic neuronal activity increases homovanillic acid levels in cerebrospinal fluid. J Neurochem. 47:1986;665-667.
47. Steinberg JL, Garver DL, Moeller FG, et al. Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatry Res. 48:1993;93-106.
48. Suzuki E, Kanba S, Nibuya M, et al. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients. Biol Psychiatry. 36:1994;654-662.
49. Tamminga C, Thaker G, Buchanan RW, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 49:1992;522-530.
50. Tassin JP, Herve D, Simon H, et al. Longterm receptor regulation induced by denervation of heterologous afferent fibers Functional significance . Fuxe K, Agnati LF. Receptor-Receptor Interactions. 1986;260-271 Plenum, New York.
51. Van Kammen DP, Rosen J, Peters J, et al. Are there state-dependent markers in schizophrenia? Psychopharmacol Bull. 21:1985;497-502.
52. Van Kammen DP, Peters J, Yao J, et al. Norepinephrine in acute exacerbations of chronic schizophrenia Negative symptoms revisited . Arch Gen Psychiatry. 47:1990;161-168.
53. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.